With shares of Toyota Motor (NYSE:TM) trading around $128, is TM an OUTPERFORM, WAIT AND SEE, or STAY AWAY? Let�� analyze the stock with the relevant sections of our CHEAT SHEET investing framework:
T = Trends for a Stock’s MovementToyota Motor is a Japan-based company mainly engaged in the automobile business and financial business. The company operates through three business segments: Automobile, Finance, and Others. Through its segments, Toyota Motor designs, manufactures, and sells vehicles as well as related parts and accessories; offers financial services related to the sale of its products; and is involved in the design, manufacture, and sale of housing, information, and communication businesses. Vehicles and related products are seeing increased innovation and Toyota Motor is at the head of this trend. Toyota has been dominating the competition and has been first to provide new technologies so look for the company to continue innovating.
Toyota is still the world�� largest car manufacturer by volume, according to January-through-September sales data released by the Japanese automaker. Toyota beat out rivals General Motors (NYSE:GM) and Volkswagen (VLKAY.PK). Toyota�� strong sales in the U.S. pushed the automaker to unload 7.412 million vehicles in the year to date. General Motors came in second, with 7.25 million vehicles, and Volkswagen sold 7.03 million cars.
Top Gas Companies To Buy For 2015: Fifth Street Finance Corp (FSC)
Fifth Street Finance Corp. is a specialty finance company that lends to and invests in small and mid-sized companies in connection with investments by private equity sponsors. The Company�� investment objective is to maximize its portfolio's total return by generating current income from its debt investments and capital appreciation from its equity investments. As of September 30, 2011, 90.9% of its portfolio consisted of debt investments that were secured by first or second priority liens on the assets of its portfolio companies. As of September 30, 2011, it held equity investments consisting of common stock, preferred stock or other equity interests in 27 out of 65 portfolio companies. It is managed and advised by Fifth Street Management LLC. In June 2013, Fifth Street Finance Corp. announced that it has closed its portfolio company acquisition of Healthcare Finance Group, LLC (HFG).
Investments
The Company tailors the terms of its debt investments to the facts and circumstances of the transaction and prospective portfolio company. As of September 30, 2011, it directly originated a majority of its debt investments. It is focusing its origination efforts on first lien, second lien and subordinated loans. Its first lien loans have terms of four to six years, provide for a variable or fixed interest rate, contain prepayment penalties and are secured by a first priority security interest in all existing and future assets of the borrower. Its first lien loans may take many forms, including revolving lines of credit, term loans and acquisition lines of credit. Its second lien loans have terms of four to six years, provide for a fixed interest rate, contain prepayment penalties and are secured by a second priority security interest in all existing and future assets of the borrower. Its second lien loans often include payment-in-kind (PIK), interest, which represents contractual interest accrued and added to the principal that generally becomes due at maturity. Its unsecured inve! stments have terms of five to six years and provide for a fixed interest rate. It may make unsecured investments on a stand-alone basis, or in connection with a senior secured loan, a junior secured loan or a one-stop financing. Its unsecured investments may include payment-in-kind (PIK), interest, which represents contractual interest accrued and added to the principal that becomes due at maturity, and an equity component, such as warrants to purchase common stock in the portfolio company.
In addition, the Company from time to time non-control, equity co-investments in connection with private equity sponsors. It structures equity investments, such as direct equity co-investments, to provide the Company with minority rights provisions and event-driven put rights. The Company make investments in the private equity funds of certain of its equity sponsors. It makes these investments where it has a long term relationship and is comfortable with the sponsor�� business model and investment strategy. As of September 30, 2011, it had investments in six private equity funds, which represented less than 1% of the fair value of its assets as of such date.
Portfolio Management
As a business development company, the Company offers managerial assistance to its portfolio companies and to provide it if requested. It monitors the financial trends of each portfolio company to assess the appropriate course of action for each company and to evaluate overall portfolio quality. It has several methods of evaluating and monitoring the performance of its investments, which includes review of monthly and quarterly financial statements and financial projections for portfolio companies; periodic and regular contact with portfolio company management; attendance at board meetings; periodic formal update interviews with portfolio company management, and assessment of business development, including product development, profitability and the portfolio company�� overall adherence to its busine! ss plan.
In addition to various risk management and monitoring tools, the Company uses an investment rating system to characterize and monitor the credit profile and expected level of returns on each investment in itd portfolio. It uses a five-level numeric rating scale. In the event that it determines that an investment is underperforming, or circumstances suggest that the risk associated with a particular investment has significantly increased, it monitors the effected portfolio company.
Valuation of Portfolio Investments
As a business development company, the Company invests in illiquid securities, including debt and equity investments of small and mid-sized companies. The Company perform valuations of its debt and equity investments on an individual basis, using market, income, and bond yield approaches as appropriate. Under the market approach, it estimates the enterprise value of the portfolio companies, in which it invests. To estimate the enterprise value of a portfolio company, it analyze various factors, including the portfolio company�� historical and projected financial results. It requires portfolio companies to provide annual audited and quarterly and monthly unaudited financial statements, as well as annual projections for the upcoming fiscal year.
Under the income approach, the Company prepares and analyze discounted cash flow models based on projections of the future free cash flows of the business. Under the bond yield approach, it uses bond yield models to determine the present value of the future cash flow streams of its debt investments. It reviews various sources of transactional data, including private mergers and acquisitions involving debt investments with similar characteristics, and assess the information in the valuation process.
Advisors' Opinion:- [By Eric Volkman]
Fifth Street Finance (NASDAQ: FSC ) is about to expand its capital base. The company has launched a fresh issue of 13.5 million shares of its common stock in an underwritten public offering. It also intends to grant its underwriters a purchase option for an additional 2.025 million shares.
- [By Jordan Wathen]
Its recent filing is for five-year unsecured debt. Other BDCs with investment-grade ratings have found good reception for five-year, unsecured note issuances. Fifth Street Finance (NASDAQ: FSC ) , a BDC with a BBB- rating from Standard & Poor's, raised $250 million in February at a 3.5% spread to five-year U.S. Treasury yields at the time. (It's worth pointing out that Fifth Street Finance's rating is one tier below FS Investment's BBB.)
- [By Eddie Staley]
Fifth Street Finance (NASDAQ: FSC) shares were also up, gaining 0.70 percent to $10.04 after the company lifted its monthly dividend by 10% to 9.17 cents per share versus 8.33 cents per share.
10 Best Diversified Bank Stocks To Watch Right Now: Cell Therapeutics Inc (CTIC)
Cell Therapeutics, Inc. (CTI), incorporated in 1991, develops, acquires and commercializes treatments for cancer. The Company�� research, development, acquisition and in-licensing activities concentrate on identifying and developing new ways to treat cancer. As of December 31, 2011, CTI focused its efforts on Pixuvri (pixantrone dimaleate) (Pixuvri), OPAXIO (paclitaxel poliglumex) (OPAXIO), tosedostat, brostallicin and bisplatinates. As of December 31, 2011, it developed Pixuvri, an anthracycline derivative for the treatment of hematologic malignancies and solid tumors. Another late-stage drug candidate of the Company, OPAXIO, is being studied as a potential maintenance therapy for women with advanced stage ovarian cancer, who achieve a complete remission following first-line therapy with paclitaxel and carboplatin. As of December 31, 2011, it also developed tosedostat in collaboration with Chroma Therapeutics, Ltd. (Chroma). On May 31, 2012, CTI completed its acquisition gaining worldwide rights to S*BIO Pte Ltd.'s (S*BIO) pacritinib.
Pixuvri
As of December 31, 2011, the Company developed Pixuvri, an aza-anthracenedione derivative, for the treatment of non-Hodgkin�� lymphoma (NHL), and various other hematologic malignancies, and solid tumors. Pixuvri was studied in the Company�� EXTEND, or PIX301, clinical trial, which was a phase III single-agent trial of Pixuvri for patients with relapsed, refractory aggressive NHL who received two or more prior therapies and who were sensitive to treatment with anthracyclines. On September 28, 2011, CTI announced that a second independent radiology assessment of response and progression endpoint data from its PIX301 clinical trial of Pixuvri was achieved with statistical significance. The results of the EXTEND trial met its primary endpoint and showed that patients randomized to treatment with Pixuvri achieved a significantly higher rate of confirmed and unconfirmed complete response compared to patients treated with standard chem! otherapy had a significantly increased overall response rate and experienced a statistically significant improvement in median progression free survival. Pixuvri had predictable and manageable toxicities when administered at the proposed dose and schedule in the EXTEND clinical trial in heavily pre-treated patients. In March 2011, the Company initiated the PIX-R trial to study Pixuvri in combination with rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL). Pixuvri has also been studied in patients with HER2-negative metastatic breast cancer who have tumor progression after at least two, but not more than three, prior chemotherapy regimens. In the second quarter of 2010, the NCCTG opened this phase II study for enrollment. The study is closed to accrual and results are expected to be reported by the NCCTG later in 2012.
OPAXIO
OPAXIO is the Company�� biologically-enhanced chemotherapeutic agent that links paclitaxel to a biodegradable polyglutamate polymer, resulting in a new chemical entity. As of December 31, 2011, the Company focused its development of OPAXIO on ovarian, brain, esophageal, head and neck cancer. OPAXIO was designed to improve the delivery of paclitaxel to tumor tissue while protecting normal tissue from toxic side effects. In November 2010, results were presented by the Brown University Oncology Group from a phase II trial of OPAXIO combined with temozolomide (TMZ), and radiotherapy in patients with newly-diagnosed, high-grade gliomas, a type of brain cancer. The trial demonstrated a high rate of complete and partial responses and a high rate of six month progression free survival (PFS). Based on these results, the Brown University Oncology Group has initiated a randomized, multicenter, phase II study of OPAXIO and standard radiotherapy versus TMZ and radiotherapy for newly diagnosed patients with glioblastoma with an active gene termed MGMT that reduces responsiveness to TMZ. A phase I/II study of OPAXIO combined with radi! otherapy ! and cisplatin was initiated by SUNY Upstate Medical University, in patients with locally advanced head and neck cancer.
Tosedostat
In March 2011, the Company entered into a co-development and license agreement with Chroma Therapeutics, Ltd. (Chroma), providing the Company with marketing and co-development rights to Chroma�� drug candidate, tosedostat, in North, Central and South America. Tosedostat is an oral, aminopeptidase inhibitor that has demonstrated anti-tumor responses in blood related cancers and solid tumors in phase I-II clinical trials. Interim results from the phase II OPAL study of tosedostat in elderly patients with relapsed or refractory acute myeloid leukemia (AML) showed that once-daily, oral doses of tosedostat had predictable and manageable toxicities and results demonstrated response rates, including a high-response rate among patients who received prior hypomethylating agents, which are used to treat myelodysplastic syndrome (MDS), a precursor of AML.
Brostallicin
As of December 31, 2011, the Company developed brostallicin through its wholly owned subsidiary, Systems Medicine LLC, which holds rights to use, develop, import and export brostallicin. Brostallicin is a synthetic deoxyribonucleic acid (DNA) minor groove binding agent that has demonstrated anti-tumor activity and a favorable safety profile in clinical trials, in which more than 230 patients have been treated as of December 31, 2011. The Company uses a genomic-based platform to guide the development of brostallicin. A phase II study of brostallicin in relapsed, refractory soft tissue sarcoma met its predefined activity and safety hurdles and resulted in a first-line phase II clinical trial study that was conducted by the European Organization for Research and Treatment of Cancer (EORTC).
The Company competes with Bristol-Myers Squibb Company, Sanofi-Aventis, Pfizer, Roche Group, Genentech, Inc., Astellas Pharma, Eli Lilly and Company, Celgene, Telik, I! nc., TEVA! Pharmaceuticals Industries Ltd. and PharmaMar.
Advisors' Opinion:- [By Nathalie Tadena]
Among the companies with shares expected to actively trade in Friday’s session are Vanda Pharmaceuticals Inc.(VNDA), Kimberly-Clark(KMB) and Cell Therapeutics(CTIC).
10 Best Diversified Bank Stocks To Watch Right Now: Spherix Inc (SPEX)
Spherix Incorporated (Spherix), incorporated on May 1, 1992, is a scientific research company. The Company is engaged in developing biopharmaceutical products and providing technical and regulatory consulting services to food, consumer products and pharmaceutical companies. The Company operates in two segments: Biospherics Incorporated (Biospherics), the Company's biotechnology research and development business, and Health Sciences, a technical and regulatory consulting business. The Company has created two wholly owned subsidiaries, Biospherics Incorporated and Spherix Consulting, Inc. (Spherix Consulting), for its two operating segments. The Company's Health Sciences contracts are in the name of Spherix Consulting, and the Company's patents are in the name of Biospherics Incorporated. Spherix provides management, strategic guidance, business development, marketing and other services to its subsidiaries. In September 2013, Spherix Incorporated closed on the acquisition of North South Holdings Inc.
Biospherics
The Company focuses its studies on treating high triglycerides and other dyslipidemias with a combination of D-tagatose and SPX-106, a licensed drug compound, which combination is referred to as SPX-106T. Spherix Consulting provides scientific and strategic support for suppliers, manufacturers, distributors and retailers of conventional foods, biotechnology-derived foods, medical foods, infant formulas, food ingredients, dietary supplements, food contact substances, pharmaceuticals, medical devices, consumer products, and industrial chemicals and pesticides. Biospherics has also completed a global Phase III clinical trial investigating the use of D-Tagatose, a stereoisomer of fructose, as a treatment for glycemic control in patients with Type 2 diabetes.
Health Sciences
The Company's Health Sciences business provides technical and regulatory consulting services to biotechnology and pharmaceutical companies, as well as providing technical suppo! rt for its research and development activities. During the year ended December 31, 2011, Health Sciences provided services to 20 companies. The projects range from safety analyses of food ingredients to safety analyses of pharmaceutical manufacturing and dispensing equipment. Health Sciences is also monitoring and directing the clinical trials for Biospherics.
Advisors' Opinion:- [By Paul Ausick]
Cisco Systems Inc. (NASDAQ: CSCO) bounced lower today, down 1.19% to $22.06 in a 52-week range of $19.98 to $26.49. Share volume was about equal to the daily average of around 42.7 million shares traded. The networking giant was hit with a lawsuit charging that Cisco violates 11 patents owned by Spherix Inc. (NASDAQ: SPEX) and that virtually all of Cisco�� revenues from switches and routers since 2008 were generated from the patent infringements.
10 Best Diversified Bank Stocks To Watch Right Now: Weis Markets Inc.(WMK)
Weis Markets, Inc. engages in the retail sale of food in Pennsylvania and surrounding states. Its retail food stores sell groceries, dairy products, frozen foods, meats, seafood, fresh produce, floral, pharmacy services, deli products, prepared foods, bakery products, beer and wine, fuel and general merchandise items, such as health and beauty care, and household products. The company operates stores primarily under the Weis Markets trade name. As of February 13, 2012, it operated 161 stores in Pennsylvania, Maryland, New York, New Jersey, and West Virginia. The company was founded in 1912 and is based in Sunbury, Pennsylvania.
Advisors' Opinion:- [By Rich Duprey]
Mid-Atlantic grocery store chain�Weis Markets (NYSE: WMK ) announced yesterday its third-quarter dividend of $0.30 per share, the same rate it's paid for the past six quarters.
10 Best Diversified Bank Stocks To Watch Right Now: Helix Energy Solutions Group Inc (HLX)
Helix Energy Solutions Group, Inc.( Helix), incorporated on November 17,1983, is an international offshore energy company that provides specialty services to the offshore energy industry, with a focus on its growing well intervention and robotics operations. The Company had had two business segments: Contracting Services and Production Facilities. Its Contracting Services seek to provide services and methodologies which it believes are critical to developing offshore reservoirs and maximizing production economi regions. Its Production Facilities segment consists of its majority ownership of a dynamically positioned floating production vessel ( Helix Producer I or HP I). In June 2013, Helix Energy Solutions Group Inc closed the previously announced sale of its pipelay vessel, the Caesar, to Trevaskis Ltd.
In January 2012, it sold its oil and gas properties within the Main Pass area of the Gulf of Mexico. On September 26, 2012, the Company sold its pipelay vessel, Intrepid, to Stabbert Maritime Holdings, LLC. On February 6, 2013, it sold Energy Resource Technology GOM, Inc. (ERT), a former wholly-owned United States subsidiary that conducted its oil and gas operations in the Gulf of Mexico.
Contracting Services Operations
The Company provides services and methodologies which it believes are critical to developing offshore reservoirs and maximizing production economics. Its life of field services are segregated into four disciplines: well intervention, robotics, subsea construction and production facilities. It provides a full range of contracting services primarily in the Gulf of Mexico, North Sea, Asia Pacific and West Africa regions primarily in deepwater.
The Company's services include production, which includes inspection, repair and maintenance of production structures, trees, jumpers, risers, pipelines and subsea equipment, well intervention, life of field support and intervention engineering; reclamation and remediation services include pluggin! g and abandonment services, pipeline abandonment services and site inspections; installation of subsea pipelines, flowlines, control umbilicals, manifold assemblies and risers, pipelay and burial, installation and tie-in of riser and manifold assembly, commissioning, testing and inspection, and cable and umbilical lay and connection. It provides oil and natural gas processing services to oil and natural gas companies, primarily those operating in the deepwater of the Gulf of Mexico using its HP I vessel. The HP I is being utilized to process production from the Phoenix.
The Company engineers, manages and conducts well construction, intervention and asset retirement operations in water depths ranging from 200 to 10,000 feet. Three of its vessels serve as work platforms for well intervention services at costs that are typically significantly less than offshore drilling rigs. In the Gulf of Mexico, its multi-service semi-submersible vessel, the Q4000, has set a series of well intervention firsts in increasingly deeper water without the use of a traditional drilling rig. In August 2012, it acquired the Discoverer 534 drillship from a subsidiary of Transocean Ltd.
The Company operates remotely operated vehicles ( ROVs), trenchers and ROVDrills designed for offshore construction and well intervention services. As global marine construction support moves to deeper water. Its chartered vessels add value by supporting deployment of its ROVs. It provides its customers with vessel availability and schedule flexibility to meet the technological challenges of their subsea activities worldwide. Its robotics assets include 49 ROVs, four trencher systems and two ROVDrills. It operate in the Gulf of Mexico, North Sea, Asia Pacific and West Africa regions. It charters four vessels to support its robotics operations and it has engaged additional vessels on short-term (spot) charters as needed. In 2012, its robotics operations had 377 vessel utilization days and 16% of global revenues derived from! alternat! ive energy contracts. Subsea construction services include the use of umbilical lay and pipelay vessels and ROVs to develop fields in the deepwater.
The Company owns interests in two production facilities in hub locations where there is potential for subsea tieback activity. It has invested in two over-sized facilities that allow the operators of these fields to tie back without burdening the operator of the hub reservoir. It owns a 50% interest in Deepwater Gateway, which owns the Marco Polo TLP located in 4,300 feet of water in the Gulf of Mexico. It also owns a 20% interest in Independence Hub which owns the Independence Hub platform, a 105-foot deep draft, semi-submersible platform located in a water depth of 8,000 feet that serves as a regional hub for up to one billion cubic feet (Bcf) of natural gas production per day from multiple ultra-deepwater fields in the eastern Gulf of Mexico.
The Company competes with Oceaneering International, Inc., Saipem S.p.A., Fugro N.V., DOF ASA, Aker Solutions ASA, Subsea 7 S.A., Technip, McDermott International, Inc., Island Offshore and Edison Chouest Offshore Companies.
Advisors' Opinion:- [By David Smith]
Helix Energy Solutions Group (NYSE: HLX )
At $2.70 billion in market capitalization, Helix is equidistant between Flotek and Superior from a size perspective. The company operates through two segments: contracting services and production facilities. - [By GuruFocus]
Helix Energy Solutions Group Inc (HLX): PRESIDENT & CEO Owen E Kratz Bought 50,000 Shares PRESIDENT & CEO of Helix Energy Solutions Group Inc (HLX) Owen E Kratz bought 50,000 shares on 10/24/2013 at an average price of $24.03. Helix Energy Solutions Group Inc has a market cap of $2.54 billion; its shares were traded at around $24.03 with and P/S ratio of 2.96.
10 Best Diversified Bank Stocks To Watch Right Now: Alnylam Pharmaceuticals Inc.(ALNY)
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, engages in discovering, developing, and commercializing novel therapeutics based on RNA interference (RNAi). Its core product programs under clinical or pre-clinical development include ALN-TTR, a Phase I clinical trial program for the treatment of transthyretin-mediated amyloidosis; ALN-APC, a Phase I clinical trial program for the treatment of hemophilia; ALN-PCS for the treatment of severe hypercholesterolemia; ALN-HPN, a pre-clinical development for the treatment of refractory anemia; and ALN-TMP, a pre-clinical development for the treatment of hemoglobinopathies, including beta-thalassemia and sickle cell anemia. The company?s partner-based programs comprise ALN-RSV01, a Phase II clinical trial program for the treatment of respiratory syncytial virus infection; ALN-VSP, a Phase I clinical trial completed program for the treatment of liver cancers; and ALN-HTT, a pre-clinical development for the treatment of Huntington?s disease. It has strategic alliances with Novartis Pharma AG; F. Hoffmann-La Roche Ltd; Takeda Pharmaceutical Company Limited; Isis Pharmaceuticals, Inc.; Medtronic Inc.; Kyowa Hakko Kirin Co., Ltd.; and Cubist Pharmaceuticals, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.
Advisors' Opinion:- [By Dan Carroll]
Biotech's known for volatility, and one of this year's biggest booms suffered a hit on that end this week. Alnylam Pharmaceuticals (NASDAQ: ALNY ) , which has seen shares explode for gains of more than 142% year to date in 2013, lost more than 11% this past week to rank as one of biotech's biggest busts over the last five days.
- [By Sean Williams]
RNAi therapeutics expert Alnylam Phrmaceuticals (NASDAQ: ALNY ) also delivered big gains this week to the tune of 22% after reporting very encouraging mid-stage data for ALN-TTR02, its treatment targeting TTR-mediated amyloidosis. Its experimental drug ALN-TTR02 delivered a 93% reduction in TTR rates in patients, which is perfectly consistent with its early stage results that demonstrated a reduction in TTR rates of 94%. Peak sales estimates, should the drug be approved, range from $800 million to up to $2 billion, but I'd caution investors keep a level head on their shoulders in the meantime.
- [By Dan Carroll]
Yet no stock in biotech had a week like Alnylam Pharmaceuticals (NASDAQ: ALNY ) , whose stock shot up more than 32% over the past five days. Company shares rocketed up 19% on Thursday alone, after the company released early-stage clinical results that showed Alnylam's developmental therapy ALN-TTRsc, a treatment for a rare genetic disorder, reduced levels of the disease, transthyretin (or TTR) amyloidosis, by 80%. Alnylam also noted that the drug had been well received by clinical subjects, a critical key for investors cautious about the drug's safety.
- [By Keith Speights]
Early validation
Alnylam Pharmaceuticals (NASDAQ: ALNY ) was another big winner this week, with shares jumping 32%. Good news from an early-stage study powered the stock's climb.
10 Best Diversified Bank Stocks To Watch Right Now: Powershares Aerospace & Defense Portfolio (PPA)
The PowerShares Aerospace & Defense Portfolio (Fund) seeks to replicate, before fees and expenses, the SPADE Defense Index. The SPADE Defense Index is designed to identify a group of companies involved in the development, manufacturing, operations and support of United States defense, homeland security and aerospace operations.
With a portfolio defined by the underlying SPADE Defense Index, constituents represent a diversified offering of large, mid and small cap companies. The constituents also enables the Fund to capture current and future spending in areas, such as armor for vehicles and soldiers, night vision systems, border security and secure communications.
Advisors' Opinion:- [By Mark Salzinger]
This industry's two largest ETFs��Shares Aerospace and Defense (ITA) and PowerShares Aerospace and Defense (PPA)��ained more than 50% last year.
No comments:
Post a Comment